J&J, AbbVie cancer drug significantly slows progression of rare lymphoma: study
By Michael Erman (Reuters) – Johnson & Johnson and AbbVie’s big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two…
